The Valley Desk

NCT04165096 · Interventional trial

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Overall registry status Completed

Phase 2

Conditions Carcinoma, Non-Small-Cell Lung

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov